| Schedule of antidilutive shares | |
| | | |
| | | |
| | | |
| | |
| | |
Three Months Ended March 31, | |
Six Months Ended March 31, |
| | |
2026 | |
2025 | |
2026 | |
2025 |
| Warrants to purchase common stock | |
| — | | |
| 3,650,000 | | |
| — | | |
| 3,650,000 | |
| Series A convertible preferred stock | |
| 6 | | |
| 6 | | |
| 6 | | |
| 6 | |
| Series B convertible preferred stock | |
| 14,080,240 | | |
| 15,580,240 | | |
| 14,080,240 | | |
| 15,580,240 | |
| Convertible notes | |
| — | | |
| 20,000 | | |
| — | | |
| 20,000 | |
| Total potentially dilutive securities | |
| 14,080,246 | | |
| 19,250,246 | | |
| 14,080,246 | | |
| 19,250,246 | |